Rapid detection micro-fluidic chip and detection method for prostate cancer marker

By designing a microfluidic chip for rapid detection of prostate cancer markers, using the color development characteristics of microfluidic chips and nanomaterials, rapid screening of prostate cancer is achieved, solving the problems of cumbersome operations and low premature screening rate in the existing technology. , provides a simple and efficient detection method.

CN118904412AActive Publication Date: 2024-11-08NANTONG UNIV

Patent Information

Application Number
CN202411037647.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-08
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

The existing prostate cancer screening methods are cumbersome to operate, have a long detection cycle, and lack a rapid detection device suitable for home self-testing, resulting in a low premature screening rate.

Method used

A quick-detection microfluidic chip for prostate cancer markers was designed. Using the sample separation function of the microfluidic chip and the color development characteristics of nanomaterials, free prostate-specific antigens were calculated semi-quantitatively by measuring the color development length of the color development channel. Concentrations of F-PSA and total prostate-specific antigen T-PSA and their ratios.

Benefits of technology

It realizes rapid screening of prostate cancer, simplifies the sample preprocessing process, improves detection efficiency, reduces costs, and is suitable for immediate self-testing in families.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118904412A_ABST
    Figure CN118904412A_ABST
Patent Text Reader

Abstract

The invention provides a rapid detection micro-fluidic chip for a prostatic cancer marker and a detection method, and belongs to the technical field of rapid screening of prostatic cancer. The technical problems that an existing detection method is tedious in operation and long in detection period are solved. According to the technical scheme, the micro-array structure is used for blood separation, and the developing micro-channel structure is used for detecting free prostate specific antigen F-PSA and total prostate specific antigen T-PSA. A blood separation structure is formed by a microarray formed by V-shaped grooves, and red blood cells, white blood cells and platelet large-particle substances in blood are separated in a physical separation mode; functional fragments for capturing F-PSA and T-PSA are respectively fixed in the developing micro-channel structure in advance, and semi-quantitative detection of F-PSA and T-PSA is realized by measuring the developing length of the developing micro-channel. The micro-fluidic chip has the beneficial effects that the operation is simple and convenient, the result is easy to read, and the analysis is rapid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of rapid screening of prostate cancer, and in particular to a rapid detection microfluidic chip and a detection method for prostate cancer markers. Background Art

[0002] Prostate cancer is one of the most common cancers in men. Due to the hidden symptoms in the early stage and the lack of clinical specific symptoms, most prostate cancer patients in my country have already progressed to the middle and late stages of the disease when they are first diagnosed, which needs to be taken seriously by the majority of men. Prostate cancer has become a "double-high" malignant tumor with a rapid increase in incidence and a rapid increase in mortality in my country in the past 10 years. According to the latest data from the China Cancer Burden Report released by the National Cancer Center, the incidence and mortality of prostate cancer in my country have continued to increase, and prostate cancer has become the sixth most common malignant tumor in Chinese men. If prostate cancer is discovered in the early stage, the 5-year survival rate after radical treatment can almost reach 100%, while if it is not treated until the middle and late stages, the 5-year survival rate of patients is only 30%. Therefore, strengthening screening, early diagnosis and treatment of high-risk groups is an important means to improve the overall survival rate of prostate cancer patients in China.

[0003] At present, screening for prostate-specific antigen PSA is the preferred recommended screening method for prostate cancer. In clinical practice, the ratio of free prostate-specific antigen F-PSA to total prostate-specific antigen T-PSA in serum is often used as the basis for the diagnosis of prostate cancer, but the acquisition of serum samples requires the centrifugation of the collected blood samples by the centrifugation equipment of the hospital's central laboratory. The clinical detection methods of F-PSA and T-PSA generally use fluorescent immunoassay, radioimmunoassay or electrochemiluminescence. These detection methods have the disadvantages of cumbersome operating steps, long detection cycle, and high analysis cost; in addition, many male patients are bound by traditional ideas and are afraid to seek medical treatment, which also reduces the early screening rate of prostate cancer. Therefore, it is urgent to develop a rapid detection device for prostate cancer biomarkers suitable for home self-testing.

[0004] With the rapid development of materials science, micro-electromechanical processing technology and microelectronics, the manufacturing technology of microfluidic chips has also been rapidly improved. It can integrate the basic operation units involved in conventional biochemical analysis, such as sample pretreatment, dilution, reagent addition, reaction, and detection, into a chip made of solid phase materials such as silicon, glass, plastic or metal, which is a few square centimeters or even smaller. The chip is formed by a network of various micro-nano pipes, and controllable fluids run through the entire system to realize various functions of conventional chemical or biological laboratories. At present, microfluidic chips have been widely used in biomedicine, chemical analysis, biosensing, high-throughput screening, environmental monitoring, food safety, and national defense security. It has the advantages of controllable liquid flow, less consumption of samples and reagents, and fast analysis speed. In 2017, the Ministry of Science and Technology of China positioned microfluidic chips as a "disruptive technology."

[0005] Therefore, combining the sample separation function of the microfluidic chip and the color change characteristics of metal nanomaterial aggregation is completely suitable for the development of a microfluidic chip for the instant detection of prostate cancer biomarkers. Summary of the invention

[0006] The purpose of the present invention is to provide a rapid detection microfluidic chip and detection method for prostate cancer markers. The present invention can meet the needs of rapid screening of prostate cancer and the rapid detection microfluidic chip for prostate cancer markers that meet the needs of family self-testing. In the present invention, combined with the convenience of separating large particles such as red blood cells, white blood cells, platelets, etc. in blood samples by the physical structure of the microfluidic chip and the advantages of nanomaterials aggregation and color development in the channel, a method for semi-quantitatively calculating the concentrations of F-PSA and T-PSA and their ratio by measuring the color development length of the color development channel is proposed.

[0007] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is specifically as follows: a rapid detection microfluidic chip for prostate cancer markers, wherein the microfluidic chip is divided into an upper and a lower layer, wherein the lower layer is a substrate with a supporting function; and the upper surface of the upper layer is provided with a sample filling port 3, a nanomaterial filling port 4 and a waste liquid discharge port 5 in sequence;

[0008] The lower surface is provided with a sample inflow channel 6, a blood separation area 7, a separated sample outflow channel 8, a sample and nanomaterial mixing pool 9, a nanomaterial inflow channel 10, a mixed sample outflow channel I11, a mixed sample outflow channel II12, a color development microchannel I13 for detecting free prostate-specific antigen F-PSA, a color development channel II14 for detecting total prostate-specific antigen T-PSA, a waste liquid outflow channel I15 and a waste liquid outflow channel II16 in sequence;

[0009] The main part of the blood separation area 7 is composed of a microarray 17 composed of "V"-shaped grooves, and the functional fragments of F-PSA and T-PSA are respectively fixed and captured in advance in the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, and the lower layer 1 and the upper layer 2 are tightly bonded together;

[0010] The sample filling port 3 is connected to one end of the sample inflow channel 6, the other end of the sample inflow channel 6 is connected to the bottom edge of the blood separation area 7, the top edge of the blood separation area 7 is connected to one end of the separated sample outflow channel 8, and the other end is connected to the sample and nanomaterial mixing pool 9;

[0011] The sample and nano material mixing pool 9 is also connected to one end of the nano material inflow channel 10, one end of the mixed sample outflow channel I11 and one end of the mixed sample outflow channel II12 respectively, and the other end of the nano material inflow channel 10 is connected to the nano material filling port 4;

[0012] The other end of the mixed sample outflow channel I11 is connected to one end of the color development microchannel I13, the other end of the color development microchannel I13 is connected to one end of the waste liquid outflow channel I15, and the other end of the waste liquid outflow channel I15 is connected to the waste liquid discharge port 5;

[0013] The other end of the mixed sample outflow channel II12 is connected to one end of the color development channel II14 , the other end of the color development channel II14 is connected to one end of the waste liquid outflow channel II16 , and the other end of the waste liquid outflow channel II16 is connected to the waste liquid discharge port 5 .

[0014] Furthermore, the material of the lower layer 1 is polyvinyl chloride PVC, polyethylene PE, polyethylene terephthalate PET, polyvinyl chloride PVC, polymethyl methacrylate PMMA, polyetherimide PEI or glass, and its length is 100mm to 140mm, width is 40mm to 80mm, and height is 2mm to 6mm.

[0015] Further, the material of the upper layer 2 is polydimethylsiloxane PDMS, thermosetting polyester TPE, styrene PS, polycarbonate PC, PMMA, polyethylene glycol diacrylate PEGDA, perfluorinated compound PFEP / PFA / PFPE or polyurethane PU, and its length is 100mm-140mm, width is 40mm-80mm, and height is 5mm-10mm;

[0016] The sample filling port 3 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the sample filling port 3 is 5 mm to 10 mm, and the distance between the circular free end edge of the sample filling port 3 and the upper surface of the upper layer 2 is 5 mm to 10 mm.

[0017] The nano material filling port 4 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the nano material filling port 4 is 5 mm to 10 mm, and the distance between the circular free end edge of the nano material filling port 4 and the upper surface of the upper layer 2 is 60 mm to 84 mm.

[0018] The waste liquid discharge port 5 on the upper surface of the upper layer 2 is through-through, and its shape is circular, the diameter of the waste liquid discharge port 5 is 5mm-10mm, and the distance between the circular edge of the free end of the waste liquid discharge port 5 and the upper surface of the upper layer 2 adjacent to the circular edge of the free end of the waste liquid discharge port 5 is 5mm-10mm;

[0019] The sample inflow channel 6 on the lower surface of the upper layer 2 has a length of 2 mm to 8 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm;

[0020] The blood separation area 7 on the lower surface of the upper layer 2 is an isosceles trapezoidal cavity, the distance between the top and bottom of the isosceles trapezoidal cavity is 18mm-31mm, the length of the bottom is 30mm-70mm, the length of the top is 40μm-400μm, and the height of the blood separation area 7 is 20μm-100μm;

[0021] The sample outflow channel 8 has a length of 2 mm to 8 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm;

[0022] The sample and nanomaterial mixing pool 9 has a diameter of 5 mm to 10 mm and a height of 100 μm to 400 μm;

[0023] The sample and nano material flow channel 10 has a length of 10 mm to 20 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm.

[0024] Furthermore, the mixed sample outflow channel I11 and the mixed sample outflow channel II12 on the lower surface of the upper layer 2 are distributed on both sides of the nanomaterial inflow channel 10, and are symmetrically arranged. The angle between the mixed sample outflow channel I11 and the mixed sample outflow channel II12 is 30° to 60°, the length is 10mm to 23mm, the width is 40μm to 100μm, and the height is 20μm to 40μm.

[0025] The color development microchannel I13 and the color development channel II14 are arranged in parallel, and the length of the color development microchannel I13 and the color development channel II14 are both 20mm-31mm, the width is both 40μm-100μm, and the height is both 20μm-40μm;

[0026] The lengths of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both 10 mm to 12 mm, the widths are both 40 μm to 100 μm, and the heights are both 20 μm to 40 μm.

[0027] Furthermore, the microarray 17 composed of "V"-shaped grooves constitutes the main part of the blood separation area 7, the opening of the first row of "V"-shaped grooves faces the sample filling port 3, the size of the opening is 30μm~45μm, the angle of the "V"-shaped grooves is 30°~60°, the distance between the tops of adjacent sides of adjacent "V"-shaped grooves is 5μm~20μm, the opening direction of the second row of "V"-shaped grooves is consistent with the first row, the distance between the two rows of "V"-shaped grooves is 5μm~15μm, the opening of the second row of "V"-shaped grooves is located between the vertices of the two "V"-shaped grooves in the first row, and the height of the "V"-shaped grooves is 20μm~100μm, and so on. The isosceles trapezoidal chamber is covered with the microarray 17 composed of "V"-shaped grooves to constitute the main part of the blood separation area 7.

[0028] Furthermore, the functional fragments of F-PSA and T-PSA that are respectively fixed and captured in advance in the color development microchannel I13 and the color development channel II14 are antibodies, aptamers or ligands.

[0029] Furthermore, the substrate of the lower layer 1 and the material of the upper layer 2 are tightly bonded together by means of thermal bonding, anodic bonding or low temperature bonding.

[0030] In order to better achieve the above-mentioned purpose of the invention, the present invention also provides a detection method of a prostate cancer marker rapid detection microfluidic chip, comprising the following steps:

[0031] S1, directly add the blood sample to the sample filling port 3;

[0032] S2, when separated sample is observed to flow out from the end of the blood separation area 7, a solution containing nanomaterials is dripped into the nanomaterial filling port 4;

[0033] S3, after the mixed sample is respectively transported to the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, wait for 5 min to 10 min;

[0034] S4, using a ruler to measure the lengths of the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, respectively, and semi-quantitatively calculate the concentrations of F-PSA and T-PSA in the sample and the ratio therebetween.

[0035] Furthermore: the nanomaterial in step S2 is gold nanoparticles, silver nanoparticles, gold core-silver shell nanoparticles or silver core-gold shell nanoparticles, and its particle size is 25nm to 50nm.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] 1. The "V"-shaped groove microarray in the blood separation area of ​​the prostate cancer marker rapid detection microfluidic chip of the present invention can quickly separate large particles such as red blood cells, white blood cells, platelets, etc. from a blood sample by physical separation to obtain a serum sample for detection. The sample pretreatment process is simple and efficient, and the "V"-shaped groove has a stronger fixation effect on the separated substances;

[0038] 2. The prostate cancer marker rapid detection microfluidic chip of the present invention, by combining the aggregation and color development characteristics of nanomaterials, can semi-quantitatively detect the concentration of F-PSA and T-PSA and the ratio of the two by simply measuring the length of the color development channel, providing a new way for rapid screening of prostate cancer;

[0039] 3. The prostate cancer marker rapid detection microfluidic chip of the present invention effectively integrates the blood sample pretreatment process and the analysis of F-PSA and T-PSA, achieving the unification of sample pretreatment and detection, and significantly improving the detection efficiency;

[0040] 4. The prostate cancer marker rapid detection microfluidic chip of the present invention is simple to prepare, low in cost, easy to operate, and quick to analyze, and can fully meet the needs of immediate self-testing at home. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] The accompanying drawings are used to provide further understanding of the present invention and constitute a part of the specification. They are used to explain the present invention together with the embodiments of the present invention and do not constitute a limitation of the present invention.

[0042] Figure 1 Schematic diagram of the microfluidic chip for rapid detection of prostate cancer markers in the present invention.

[0043] Figure 2 for Figure 1 Top view of the .

[0044] Among them, the figure markings are: 1, lower layer; 2, upper layer; 3, sample filling port; 4, nanomaterial filling port; 5, waste liquid discharge port; 6, sample inflow channel; 7, blood separation area; 8, sample outflow channel; 9, sample and nanomaterial mixing pool; 10, nanomaterial inflow channel; 11, mixed sample outflow channel I; 12, mixed sample outflow channel II; 13, color development microchannel I; 14, color development channel II; 15, waste liquid outflow channel I; 16, waste liquid outflow channel II; 17, microarray composed of "V"-shaped grooves. DETAILED DESCRIPTION

[0045] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. Of course, the specific embodiments described here are only used to explain the present invention and are not used to limit the present invention.

[0046] Example 1

[0047] See also Figures 1 to 2 , the technical scheme provided in this embodiment is that the rapid detection microfluidic chip of prostate cancer markers of the present invention is divided into two layers, the lower layer 1 is a substrate with a supporting function; the upper surface of the upper layer 2 is sequentially provided with a sample filling port 3, a nanomaterial filling port 4, and a waste liquid discharge port 5; the lower surface is sequentially provided with a sample inlet channel 6, a blood separation area 7, a separated sample outflow channel 8, a sample and nanomaterial mixing pool 9, a nanomaterial inlet channel 10, a mixed sample outflow channel I11, a mixed sample outflow channel II12, a color development microchannel I13 for detecting free prostate-specific antigen F-PSA, a color development channel II14 for detecting total prostate-specific antigen T-PSA, a waste liquid outflow channel I15 and a waste liquid outflow channel II16, wherein the main part of the blood separation area is composed of a microarray 17 composed of "V"-shaped grooves, a color development microchannel 13 for detecting F-PSA and a color development channel II for detecting T-PSA. The functional fragments of F-PSA and T-PSA are pre-fixed in 14 and can be captured respectively, and the lower layer 1 and the upper layer 2 are tightly bonded together.

[0048] The material of the lower layer 1 is polyvinyl chloride (PVC), with a length of 100 mm, a width of 40 mm, and a height of 2 mm. The material of the upper layer 2 is polydimethylsiloxane (PDMS), with a length of 100 mm, a width of 40 mm, and a height of 5 mm.

[0049] The sample filling port 3 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the sample filling port 3 is 5 mm, and the distance between the circular free end edge of the sample filling port 3 and the upper surface of the upper layer 2 is 5 mm.

[0050] The nano material filling port 4 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the nano material filling port 4 is 5 mm, and the distance between the circular free end edge of the nano material filling port 4 and the upper surface of the upper layer 2 is 60 mm.

[0051] The waste liquid outlet 5 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the waste liquid outlet 5 is 5 mm, and the distance between the circular free end edge of the waste liquid outlet 5 and the upper surface of the upper layer 2 is 5 mm.

[0052] One end of the sample inflow channel 6 on the lower surface of the upper layer 2 is connected to the sample filling port 3, and has a length of 2 mm, a width of 40 μm, and a height of 20 μm.

[0053] The blood separation area 7 on the lower surface of the upper layer 2 is an isosceles trapezoidal cavity, the bottom edge of the isosceles trapezoidal cavity is connected to the other end of the sample inflow channel 6, the distance between the top edge and the bottom edge of the isosceles trapezoidal cavity is 31 mm, the length of the bottom edge is 30 mm, the length of the top edge is 40 μm, and the height of the blood separation area 7 is 20 μm.

[0054] One end of the separated sample outflow channel 8 on the lower surface of the upper layer 2 is connected to the top edge of the blood separation area 7, and has a length of 2 mm, a width of 40 μm, and a height of 20 μm.

[0055] One end of the sample and nanomaterial mixing pool 9 on the lower surface of the upper layer 2 is connected to the other end of the separated sample outflow channel 8, and its shape is circular. The diameter of the sample and nanomaterial mixing pool 9 is 5 mm and the height is 100 μm.

[0056] One end of the nanomaterial inflow channel 10 on the lower surface of the upper layer 2 is connected to the sample and nanomaterial mixing pool 9, and has a length of 10 mm, a width of 40 μm, and a height of 20 μm.

[0057] The mixed sample outflow channel I11 and the mixed sample outflow channel II12 on the lower surface of the upper layer 2 are distributed on both sides of the nanomaterial inflow channel 10 and are arranged symmetrically. One end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12 are connected to the sample and nanomaterial mixing pool 9, and the angle between them is 30°. The lengths are 10 mm, the widths are 40 μm, and the heights are 20 μm.

[0058] One end of the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA on the lower surface of the upper layer 2 are respectively connected to the other end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12, and are arranged in parallel. The color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA are both 20 mm in length, 40 μm in width, and 20 μm in height.

[0059] One end of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 on the lower surface of the upper layer 2 are respectively connected to the other end of the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, and the other ends of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both connected to the waste liquid discharge port 5. The length of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both 10 mm, the width is 40 μm, and the height is 20 μm.

[0060] The microarray 17 composed of "V"-shaped grooves constitutes the main part of the blood separation area 7. The opening of the first row of "V"-shaped grooves faces the sample filling port 3, the size of the opening is 30μm, the angle of the "V"-shaped grooves is 30°, the distance between the tops of the adjacent sides of adjacent "V"-shaped grooves is 5μm, the opening direction of the second row of "V"-shaped grooves is consistent with the first row, the distance between the two rows of "V"-shaped grooves is 5μm, the opening of the second row of "V"-shaped grooves is located between the vertices of the two "V"-shaped grooves in the first row, and the height of the "V"-shaped grooves is 20μm. By analogy, the microarray 1 composed of "V"-shaped grooves paved in the isosceles trapezoidal chamber constitutes the main part of the blood separation area 7.

[0061] The functional fragments that can capture F-PSA and T-PSA respectively are pre-fixed in the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, which are antibodies.

[0062] The substrate of the lower layer 1 and the material of the upper layer 2 are closely attached together by thermal bonding.

[0063] A method for detecting a prostate cancer marker rapid detection microfluidic chip comprises the following steps:

[0064] S1, directly add the blood sample to the sample filling port 3;

[0065] S2, when the separated sample is observed to flow out from the end of the blood separation zone 7, a solution containing gold nanoparticles with a particle size of 25 nm is dripped into the nanomaterial filling port 4;

[0066] S3, after the mixed sample is transported to the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, wait for 5 minutes;

[0067] S4, using a ruler to measure the lengths of the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA, respectively, and semi-quantitatively calculate the concentrations of F-PSA and T-PSA in the sample and the ratio therebetween.

[0068] Example 2

[0069] See also Figures 1 to 2, the technical solution provided in this embodiment is that the rapid detection microfluidic chip of prostate cancer markers of the present invention is divided into two layers, the lower layer 1 is a substrate with a supporting function; the upper surface of the upper layer 2 is sequentially provided with a sample filling port 3, a nanomaterial filling port 4, and a waste liquid discharge port 5; the lower surface is sequentially provided with a sample inlet channel 6, a blood separation area 7, a separated sample outflow channel 8, a sample and nanomaterial mixing pool 9, a nanomaterial inlet channel 10, a mixed sample outflow channel I11, a mixed sample outflow channel II12, a color development microchannel I13 for detecting free prostate-specific antigen F-PSA, a color development channel II14 for detecting total prostate-specific antigen T-PSA, a waste liquid outflow channel I15 and a waste liquid outflow channel II16, wherein the main part of the blood separation area is composed of a microarray 17 composed of "V"-shaped grooves, and the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA are pre-fixed with functional fragments that can capture F-PSA and T-PSA respectively. The lower layer 1 and the upper layer 2 are tightly bonded together.

[0070] The material of the lower layer 1 is polyethylene PE, with a length of 140 mm, a width of 80 mm, and a height of 6 mm. The material of the upper layer 2 is polyethylene glycol diacrylate PEGDA, with a length of 140 mm, a width of 80 mm, and a height of 10 mm.

[0071] The sample filling port 3 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the sample filling port 3 is 10 mm, and the distance between the circular free end edge of the sample filling port 3 and the upper surface of the upper layer 2 is 10 mm.

[0072] The nano material filling port 4 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the nano material filling port 4 is 10 mm, and the distance between the circular free end edge of the nano material filling port 4 and the upper surface of the upper layer 2 is 84 mm.

[0073] The waste liquid outlet 5 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the waste liquid outlet 5 is 10 mm, and the distance between the circular free end edge of the waste liquid outlet 5 and the upper surface of the upper layer 2 is 10 mm.

[0074] One end of the sample inflow channel 6 on the lower surface of the upper layer 2 is connected to the sample filling port 3, and has a length of 8 mm, a width of 400 μm, and a height of 100 μm.

[0075] The blood separation area 7 on the lower surface of the upper layer 2 is an isosceles trapezoidal cavity, the bottom edge of the isosceles trapezoidal cavity is connected to the other end of the sample inflow channel 6, the distance between the top edge and the bottom edge of the isosceles trapezoidal cavity is 18 mm, the length of the bottom edge is 70 mm, the length of the top edge is 400 μm, and the height of the blood separation area 7 is 100 μm.

[0076] One end of the separated sample outflow channel 8 on the lower surface of the upper layer 2 is connected to the top edge of the blood separation area 7, and has a length of 8 mm, a width of 400 μm, and a height of 100 μm.

[0077] One end of the sample and nanomaterial mixing pool 9 on the lower surface of the upper layer 2 is connected to the other end of the separated sample outflow channel 8, and its shape is circular. The diameter of the sample and nanomaterial mixing pool 9 is 10 mm and the height is 400 μm.

[0078] One end of the nanomaterial inflow channel 10 on the lower surface of the upper layer 2 is connected to the sample and nanomaterial mixing pool 9, and has a length of 20 mm, a width of 400 μm, and a height of 100 μm.

[0079] The mixed sample outflow channel I11 and the mixed sample outflow channel II12 on the lower surface of the upper layer 2 are distributed on both sides of the nanomaterial inflow channel 10 and are arranged symmetrically. One end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12 are connected to the sample and nanomaterial mixing pool 9, and the angle between them is 60°. The lengths are both 23 mm, the widths are both 100 μm, and the heights are both 40 μm.

[0080] One end of the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA on the lower surface of the upper layer 2 are respectively connected to the other end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12, and are arranged in parallel. The color development microchannel I13 for detecting F-PSA and the color development channel II 14 for detecting T-PSA are both 31 mm long, 100 μm wide, and 40 μm high.

[0081] One end of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 on the lower surface of the upper layer 2 are respectively connected to the other end of the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA, and the other ends of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both connected to the waste liquid discharge port 5. The length of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both 12 mm, the width is 100 μm, and the height is 40 μm.

[0082] The microarray 17 composed of "V"-shaped grooves constitutes the main part of the blood separation area 7. The opening of the first row of "V"-shaped grooves faces the sample filling port 3, the size of the opening is 45μm, the angle of the "V"-shaped grooves is 60°, the distance between the tops of the adjacent sides of adjacent "V"-shaped grooves is 20μm, the opening direction of the second row of "V"-shaped grooves is consistent with the first row, the distance between the two rows of "V"-shaped grooves is 15μm, the opening of the second row of "V"-shaped grooves is located between the vertices of the two "V"-shaped grooves in the first row, and the height of the "V"-shaped grooves is 100μm. By analogy, the microarray 1 composed of "V"-shaped grooves paved in the isosceles trapezoidal chamber constitutes the main part of the blood separation area 7.

[0083] The functional fragments that can capture F-PSA and T-PSA respectively are pre-fixed in the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA, which are aptamers.

[0084] The method of closely attaching the substrate of the lower layer 1 and the material of the upper layer 2 together is anodic bonding.

[0085] A method for detecting a prostate cancer marker rapid detection microfluidic chip comprises the following steps:

[0086] S1, directly add the blood sample to the sample filling port 3;

[0087] S2, when the separated sample is observed to flow out from the end of the blood separation area 7, a silver nanoparticle solution with a particle size of 50 nm is dripped into the nanomaterial filling port 4;

[0088] S3, after the mixed sample is transported to the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA, wait for 10 minutes;

[0089] S4, using a ruler to measure the lengths of the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA, respectively, and semi-quantitatively calculate the concentrations of F-PSA and T-PSA in the sample and the ratio therebetween.

[0090] Example 3

[0091] See also Figures 1 to 2The present embodiment provides a technical solution as follows: the rapid detection microfluidic chip for prostate cancer markers of the present invention is divided into two layers, the lower layer 1 is a substrate with a supporting function; the upper surface of the upper layer 2 is sequentially provided with a sample filling port 3, a nanomaterial filling port 4, and a waste liquid discharge port 5; the lower surface is sequentially provided with a sample inlet channel 6, a blood separation area 7, a separated sample outflow channel 8, a sample and nanomaterial mixing pool 9, a nanomaterial inlet channel 10, a mixed sample outflow channel I11, a mixed sample outflow channel II12, and a sample inlet channel 13 for detecting free prostate The color development microchannel I13 for detecting prostate-specific antigen F-PSA, the color development channel II14 for detecting total prostate-specific antigen T-PSA, the waste liquid outflow channel I15 and the waste liquid outflow channel II16, wherein the main part of the blood separation area is composed of a microarray 17 composed of "V"-shaped grooves, and the color development microchannel I13 for detecting F-PSA and the color development channel II14 for detecting T-PSA are pre-fixed with functional fragments that can capture F-PSA and T-PSA respectively, and the lower layer 1 and the upper layer 2 are tightly bonded together.

[0092] The material of the lower layer 1 is polyethylene terephthalate PET, with a length of 120 mm, a width of 60 mm, and a height of 4 mm; the material of the upper layer 2 is polyurethane PU, with a length of 120 mm, a width of 60 mm, and a height of 7 mm.

[0093] The sample filling port 3 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the sample filling port 3 is 8 mm, and the distance between the circular free end edge of the sample filling port 3 and the upper surface of the upper layer 2 is 8 mm.

[0094] The nano material filling port 4 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the nano material filling port 4 is 8 mm, and the distance between the circular free end edge of the nano material filling port 4 and the upper surface of the upper layer 2 is 72 mm.

[0095] The waste liquid outlet 5 on the upper surface of the upper layer 2 is through-through and circular in shape. The diameter of the waste liquid outlet 5 is 8 mm, and the distance between the circular free end edge of the waste liquid outlet 5 and the upper surface of the upper layer 2 is 8 mm.

[0096] One end of the sample inflow channel 6 on the lower surface of the upper layer 2 is connected to the sample filling port 3, and has a length of 5 mm, a width of 200 μm, and a height of 60 μm.

[0097] The blood separation area 7 on the lower surface of the upper layer 2 is an isosceles trapezoidal cavity, the bottom edge of the isosceles trapezoidal cavity is connected to the other end of the sample inflow channel 6, the distance between the top edge and the bottom edge of the isosceles trapezoidal cavity is 23 mm, the length of the bottom edge is 50 mm, the length of the top edge is 200 μm, and the height of the blood separation area 7 is 60 μm.

[0098] One end of the separated sample outflow channel 8 on the lower surface of the upper layer 2 is connected to the top edge of the blood separation area 7, and has a length of 5 mm, a width of 200 μm, and a height of 60 μm.

[0099] One end of the sample and nanomaterial mixing pool 9 on the lower surface of the upper layer 2 is connected to the other end of the separated sample outflow channel 8, and its shape is circular. The diameter of the sample and nanomaterial mixing pool 9 is 8 mm and the height is 250 μm.

[0100] One end of the nanomaterial inflow channel 10 on the lower surface of the upper layer 2 is connected to the sample and nanomaterial mixing pool 9, and has a length of 15 mm, a width of 200 μm, and a height of 60 μm.

[0101] The mixed sample outflow channel I11 and the mixed sample outflow channel II12 on the lower surface of the upper layer 2 are distributed on both sides of the nanomaterial inflow channel 10 and are arranged symmetrically. One end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12 are connected to the sample and nanomaterial mixing pool 9, and the angle between them is 45°. The lengths are both 16 mm, the widths are both 70 μm, and the heights are both 30 μm.

[0102] One end of the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA on the lower surface of the upper layer 2 are respectively connected to the other end of the mixed sample outflow channel I11 and the mixed sample outflow channel II12, and are arranged in parallel. The length of the color development microchannel I13 for detecting F-PSA and the color development channel II 14 for detecting T-PSA are both 25 mm, the width is 70 μm, and the height is 30 μm.

[0103] One end of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 on the lower surface of the upper layer 2 are respectively connected to the other end of the color development microchannel I13 for detecting F-PSA and the color development channel II 14 for detecting T-PSA, and the other ends of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both connected to the waste liquid discharge port 5. The length of the waste liquid outflow channel I15 and the waste liquid outflow channel II16 are both 9.2 mm, the width is 70 μm, and the height is 30 μm.

[0104] The microarray 17 composed of "V"-shaped grooves constitutes the main part of the blood separation area 7. The opening of the first row of "V"-shaped grooves faces the sample filling port 3, the size of the opening is 36μm, the angle of the "V"-shaped grooves is 45°, the distance between the tops of the adjacent sides of adjacent "V"-shaped grooves is 12μm, the opening direction of the second row of "V"-shaped grooves is consistent with the first row, the distance between the two rows of "V"-shaped grooves is 10μm, the opening of the second row of "V"-shaped grooves is located between the vertices of the two "V"-shaped grooves in the first row, and the height of the "V"-shaped grooves is 60μm. By analogy, the microarray 1 composed of "V"-shaped grooves paved in the isosceles trapezoidal chamber constitutes the main part of the blood separation area 7.

[0105] The functional fragments that can capture F-PSA and T-PSA respectively are pre-fixed in the color development microchannel I13 for detecting F-PSA and the color development channel I14 for detecting T-PSA, which are ligands.

[0106] The substrate of the lower layer 1 and the material of the upper layer 2 are closely attached together by low temperature bonding.

[0107] A method for detecting a prostate cancer marker rapid detection microfluidic chip comprises the following steps:

[0108] S1, directly add the blood sample to the sample filling port 3;

[0109] S2, when separated sample is observed to flow out from the end of the blood separation zone 7, a solution containing gold core-silver shell nanoparticles with a particle size of 36 nm is dripped into the nanomaterial filling port 4;

[0110] S3, after the mixed sample is transported to the color development microchannel I 13 for detecting F-PSA and the color development channel II 14 for detecting T-PSA, wait for 8 minutes;

[0111] S4, using a ruler to measure the lengths of the color development microchannel I 13 for detecting F-PSA and the color development channel II 14 for detecting T-PSA, respectively, and semi-quantitatively calculate the concentrations of F-PSA and T-PSA in the sample and the ratio therebetween.

[0112] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A microfluidic chip for rapid detection of prostate cancer markers. It is characterized in that The microfluidic chip is divided into two layers, the lower layer (1) being a substrate having a supporting function; the upper surface of the upper layer (2) is provided with a sample filling port (3), a nanomaterial filling port (4), and a waste liquid discharge port (5) in sequence; The lower surface is provided with a sample inflow channel (6), a blood separation area (7), a separated sample outflow channel (8), a sample and nanomaterial mixing pool (9), a nanomaterial inflow channel (10), a mixed sample outflow channel I (11), a mixed sample outflow channel II (12), a color development microchannel I (13) for detecting free prostate-specific antigen F-PSA, a color development channel II (14) for detecting total prostate-specific antigen T-PSA, a waste liquid outflow channel I (15) and a waste liquid outflow channel II (16) in sequence; The main part of the blood separation area (7) is composed of a microarray (17) composed of "V"-shaped grooves, and the functional fragments of F-PSA and T-PSA are respectively fixed and captured in advance in the color development microchannel I (13) for detecting F-PSA and the color development channel II (14) for detecting T-PSA, and the lower layer (1) and the upper layer (2) are tightly bonded together; The sample filling port (3) is connected to one end of the sample inflow channel (6), the other end of the sample inflow channel (6) is connected to the bottom edge of the blood separation area (7), the top edge of the blood separation area (7) is connected to one end of the separated sample outflow channel (8), and the other end is connected to the sample and nanomaterial mixing pool (9); The sample and nanomaterial mixing pool (9) is also connected to one end of the nanomaterial inflow channel (10), one end of the mixed sample outflow channel I (11) and one end of the mixed sample outflow channel II (12), respectively, and the other end of the nanomaterial inflow channel (10) is connected to the nanomaterial filling port (4); The other end of the mixed sample outflow channel I (11) is connected to one end of the color development microchannel I (13), the other end of the color development microchannel I (13) is connected to one end of the waste liquid outflow channel I (15), and the other end of the waste liquid outflow channel I (15) is connected to the waste liquid discharge port (5); The other end of the mixed sample outflow channel II (12) is connected to one end of the color development channel II (14), the other end of the color development channel II (14) is connected to one end of the waste liquid outflow channel II (16), and the other end of the waste liquid outflow channel II (16) is connected to the waste liquid discharge port (5).

2. The rapid detection microfluidic chip for prostate cancer markers according to claim 1, It is characterized in that The material of the lower layer (1) is polyvinyl chloride (PVC), polyethylene (PE), polyethylene terephthalate (PET), polyvinyl chloride (PVC), polymethyl methacrylate (PMMA), polyetherimide (PEI) or glass, and its length is 100 mm to 140 mm, width is 40 mm to 80 mm, and height is 2 mm to 6 mm.

3. The rapid detection microfluidic chip for prostate cancer markers according to claim 1, It is characterized in that The material of the upper layer (2) is polydimethylsiloxane (PDMS), thermosetting polyester (TPE), styrene (PS), polycarbonate (PC), PMMA, polyethylene glycol diacrylate (PEGDA), perfluorinated compound (PFEP / PFA / PFPE) or polyurethane (PU), and its length is 100 mm to 140 mm, width is 40 mm to 80 mm, and height is 5 mm to 10 mm; The sample filling port (3) on the upper surface of the upper layer (2) is through-through and circular in shape. The diameter of the sample filling port (3) is 5 mm to 10 mm, and the distance between the circular free end edge of the sample filling port (3) and the upper surface of the upper layer (2) is 5 mm to 10 mm. The nano material filling port (4) on the upper surface of the upper layer (2) is through-through and circular in shape. The diameter of the nano material filling port (4) is 5 mm to 10 mm, and the distance between the circular free end edge of the nano material filling port (4) and the upper surface of the upper layer (2) is 60 mm to 84 mm. The waste liquid discharge outlet (5) on the upper surface of the upper layer (2) is through-connected from top to bottom and has a circular shape. The diameter of the waste liquid discharge outlet (5) is 5 mm to 10 mm. The distance between the circular edge of the free end of the waste liquid discharge outlet (5) and the upper surface of the upper layer (2) adjacent to the circular edge of the free end of the waste liquid discharge outlet (5) is 5 mm to 10 mm. The sample inflow channel (6) on the lower surface of the upper layer (2) has a length of 2 mm to 8 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm; The blood separation area (7) on the lower surface of the upper layer (2) is an isosceles trapezoidal cavity, the distance between the top and bottom of the isosceles trapezoidal cavity is 18 mm to 31 mm, the length of the bottom is 30 mm to 70 mm, the length of the top is 40 μm to 400 μm, and the height of the blood separation area (7) is 20 μm to 100 μm; The sample outflow channel (8) has a length of 2 mm to 8 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm; The sample and nanomaterial mixing pool (9) has a diameter of 5 mm to 10 mm and a height of 100 μm to 400 μm; The nano material inflow channel (10) has a length of 10 mm to 20 mm, a width of 40 μm to 400 μm, and a height of 20 μm to 100 μm.

4. The prostate cancer marker rapid detection microfluidic chip according to claim 1, Features: The mixed sample outflow channel I (11) and the mixed sample outflow channel II (12) on the lower surface of the upper layer (2) are distributed on both sides of the nanomaterial inflow channel (10) and are symmetrically arranged. The angle between the mixed sample outflow channel I (11) and the mixed sample outflow channel II (12) is 30° to 60°, the length is 10 mm to 23 mm, the width is 40 μm to 100 μm, and the height is 20 μm to 40 μm. The color development microchannel I (13) and the color development channel II (14) are arranged in parallel, and the length of the color development microchannel I (13) and the color development channel II (14) are both 20 mm to 31 mm, the width is both 40 μm to 100 μm, and the height is both 20 μm to 40 μm; The waste liquid outflow channel I (15) and the waste liquid outflow channel II (16) have lengths of 10 mm to 12 mm, widths of 40 μm to 100 μm, and heights of 20 μm to 40 μm.

5. The rapid detection microfluidic chip for prostate cancer markers according to claim 1, It is characterized in that The microarray (17) composed of "V"-shaped grooves constitutes the main part of the blood separation area (7). The opening of the first row of "V"-shaped grooves faces the sample filling port (3), the size of the opening is 30μm to 45μm, the angle of the "V"-shaped grooves is 30° to 60°, the distance between the tops of adjacent sides of adjacent "V"-shaped grooves is 5μm to 20μm, the opening direction of the second row of "V"-shaped grooves is consistent with the first row, the distance between the two rows of "V"-shaped grooves is 5μm to 15μm, the opening of the second row of "V"-shaped grooves is located between the vertices of the two "V"-shaped grooves in the first row, and the height of the "V"-shaped grooves is 20μm to 100μm. By analogy, the isosceles trapezoidal chamber is covered with the microarray (17) composed of "V"-shaped grooves to constitute the main part of the blood separation area (7).

6. The rapid detection microfluidic chip for prostate cancer markers according to claim 1, It is characterized in that The functional fragments of F-PSA and T-PSA that are respectively fixed and captured in advance in the color development microchannel I (13) and the color development channel II (14) are antibodies, aptamers or ligands.

7. The rapid detection microfluidic chip for prostate cancer markers according to claim 1, It is characterized in that The substrate of the lower layer (1) and the material of the upper layer (2) are tightly bonded together by means of thermal bonding, anodic bonding or low temperature bonding.

8. The detection method of the prostate cancer marker rapid detection microfluidic chip according to any one of claims 1 to 7, Features: The following steps are involved: S1, directly add the blood sample to the sample filling port (3); S2, when separated sample is observed to flow out from the end of the blood separation area (7), a solution containing nanomaterials is dripped into the nanomaterial filling port (4); S3, after the mixed sample is transported to the color development microchannel I (13) for detecting F-PSA and the color development channel II (14) for detecting T-PSA, wait for 5 to 10 minutes; S4, using a ruler to measure the lengths of the colorimetric microchannel I (13) for detecting F-PSA and the colorimetric channel II (14) for detecting T-PSA, respectively, and semi-quantitatively calculate the concentrations of F-PSA and T-PSA in the sample and the ratio between them.

9. The method for detecting a prostate cancer marker rapid detection microfluidic chip according to claim 8, Features: The nanomaterial in step S2 is gold nanoparticles, silver nanoparticles, gold core-silver shell nanoparticles or silver core-gold shell nanoparticles, and the particle size thereof is 25nm-50nm.

Citation Information

Patent Citations

  • Integrated microfluidic chip for capture of cancer cells in whole blood

    CN102360010A

  • Use method of automatic sample-separating constant-volume immunofluorescence quantitative rapid detection micro-fluidic chip

    CN110568201A

  • Rapid detection device and detection method for integrated prostate cancer biomarker

    CN117129683A

  • Micro-fluidic chip for efficiently separating CTCs based on physical and immune synergy and application of micro-fluidic chip

    CN117305053A

  • Lateral flow assay strip for quantitative analysis

    KR1020120132249A

Cited By

  • PSA detection method based on droplet microfluidics

    CN122330434A